Want to join the conversation?
$GILD said that for 1Q16 it reported non-GAAP diluted EPS of $3.03 vs. $2.94 in 1Q15. Total revenues were $7.8Bil, up 3% YoverY and down 8% sequentially. Product sales were $7.7Bil, an increase of 4% YoverY and down 9% sequentially. The company said that it sees strong uptick of its newer single-tablet regimens, including Genvoya.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)